- Patent Title: Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
-
Application No.: US16688109Application Date: 2019-11-19
-
Publication No.: US10968205B2Publication Date: 2021-04-06
- Inventor: Robert Murray McKinnell , Erik Fenster , Tom M. Lam , Jerry Nzerem , Marta Dabros , Venkat R. Thalladi , Miroslav Rapta
- Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
- Applicant Address: US CA South San Francisco
- Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
- Current Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
- Current Assignee Address: US CA South San Francisco
- Agent Jeffrey A. Hagenah
- Main IPC: C07D403/12
- IPC: C07D403/12 ; C07D401/12 ; C07D413/12 ; C07D471/04 ; C07D487/04 ; A61P17/00 ; A61P1/00 ; A61P29/00 ; A61P35/00

Abstract:
The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
Public/Granted literature
- US20200216423A1 PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS Public/Granted day:2020-07-09
Information query